Experimental interferon boosts hopes for rectal cancer remission
NCT ID NCT07662278
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding a new form of interferon (rSIFN-co) to standard total neoadjuvant therapy (short-course radiation plus chemotherapy) can improve the chance of complete tumor disappearance in people with mid-low locally advanced rectal cancer. About 90 adults with this cancer will be randomly assigned to receive either the standard therapy alone or the standard therapy plus rectal interferon twice a week. The main goal is to see if more patients achieve a complete response (no cancer detectable after treatment).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- recombinant super-compound interferon (rSIFN-co)
- What this could lead to
- If successful, this combination could increase the chance of eliminating all signs of rectal cancer before surgery, potentially reducing the need for more aggressive treatments.
- What could go wrong
- This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. The added interferon may cause side effects and the complete response benefit is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MID-LOW LOCALLY ADVANCED RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.